Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The oat-containing glycerin skin protectant ointment (Oat+Gly) is a topical therapeutic formulation developed for the treatment of dry skin conditions and the enhancement of skin resiliency. Developed by researchers at Kenvue (formerly Johnson & Johnson Consumer Health), the ointment combines the humectant properties of glycerin with the bioactive components of *Avena sativa* (oat). Mechanistically, the formulation promotes the restoration of Natural Moisturizing Factors (NMFs) by enhancing the processing of filaggrin into its degradation products, such as pyrrolidone carboxylic acid (PCA) and urocanic acid (UCA). Additionally, it helps preserve hyaluronic acid (HA) levels within the skin, particularly against UV-induced degradation. Clinical data from a 3-week regression study indicate that the ointment significantly improves visual dryness, tactile roughness, and skin hydration compared to standard petrolatum-based ointments, while offering superior aesthetic qualities such as faster absorption and a non-greasy feel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oat-containing glycerin skin protectant ointment.